In vivo distribution of β2 glycoprotein I under various pathophysiologic conditions.
about
The role of the gut microbiota in the pathogenesis of antiphospholipid syndromeCatastrophic APS in the context of other thrombotic microangiopathies.Antiphospholipid and antioangiogenic activity in females with recurrent miscarriage and antiphospholipid syndrome.Antiphospholipid syndrome in 2014: more clinical manifestations, novel pathogenic players and emerging biomarkers.Platelets are required for enhanced activation of the endothelium and fibrinogen in a mouse thrombosis model of APS.Dendritic polyglycerolsulfate near infrared fluorescent (NIRF) dye conjugate for non-invasively monitoring of inflammation in an allergic asthma mouse model.Intranasal administration of recombinant TRAIL down-regulates CXCL-1/KC in an ovalbumin-induced airway inflammation murine modelAn A1-A1 mutant with improved binding and inhibition of β2GPI/antibody complexes in antiphospholipid syndrome.Maternal age effects on myometrial expression of contractile proteins, uterine gene expression, and contractile activity during labor in the ratAnti-phospholipid induced murine fetal loss: novel protective effect of a peptide targeting the β2 glycoprotein I phospholipid-binding site. Implications for human fetal loss.The complement system at the embryo implantation site: friend or foe?Prediction of adverse pregnancy outcome by the presence of lupus anticoagulant, but not anticardiolipin antibody, in patients with antiphospholipid antibodies.Identification of a Monoclonal Antibody That Attenuates Antiphospholipid Syndrome-Related Pregnancy Complications and Thrombosis.Human β2-glycoprotein I attenuates mouse intestinal ischemia/reperfusion induced injury and inflammationApoE Receptor 2 Mediation of Trophoblast Dysfunction and Pregnancy Complications Induced by Antiphospholipid Antibodies in MiceAntiphospholipid antibodies detected by line immunoassay differentiate among patients with antiphospholipid syndrome, with infections and asymptomatic carriers.Gram Negative Bacterial Inflammation Ameliorated by the Plasma Protein Beta 2-Glycoprotein I.Antiphospholipid Antibody Titers and Clinical Outcomes in Patients with Recurrent Miscarriage and Antiphospholipid Antibody Syndrome: A Prospective Study.Obstetric and vascular APS: same autoantibodies but different diseases?Antiphospholipid antibodies mediate autoimmunity against dying cells.Top 10 clinical research developments in antiphospholipid syndrome.Epigenetics and Systemic Lupus Erythematosus: Unmet Needs.Posttranslational forms of beta 2-glycoprotein I in the pathogenesis of the antiphospholipid syndromeΒeta 2-glycoprotein I protects mice against gram-negative septicaemia in a sexually dimorphic manner.Anti-beta-2 glycoprotein I epitope specificity: from experimental models to diagnostic tools.Autoantibody response and pregnancy-related pathology induced by combined LPS and tetanus toxoid hyperimmunization in BALB/c and C57BL/6 mice.Low molecular weight heparin and aspirin exacerbate human endometrial endothelial cell responses to antiphospholipid antibodies.Diagnosing antiphospholipid syndrome: 'extra-criteria' manifestations and technical advances.Pathogenic Role of Complement in Antiphospholipid Syndrome and Therapeutic Implications.Multiple dye-doped NIR-emitting silica nanoparticles for both flow cytometry and in vivo imaging
P2860
Q26866133-DF5A7EE6-5EB0-4CD4-9019-203BDF7E3EE1Q33419886-DBD0CAA7-9D70-491F-9BC7-CAB435F34B51Q33435408-D6DD4CC9-8626-4CF5-ACCA-4A6E784B37A9Q33766670-0D83308B-CB35-41A6-9C83-D6A9F116AA0AQ33948737-A8EE536F-AE5E-4D36-9C84-432615A96029Q34600144-669BA4D4-37A2-418D-A92F-251D5B412FFEQ34704284-4D18D6D2-9A37-4BE9-BB1F-2B26A01D1264Q35152055-AED272E1-53B7-40B8-9635-32A326261210Q35588574-75EF9E2E-AF3C-4E17-BB87-A2014B1F7A5BQ35854768-CEBCB2B9-1CA0-4E53-A0A6-47B1B48D4CA5Q35927443-C89896D5-5B17-49E6-A8F2-A7AE072E3A9DQ35977256-D8107491-4D27-478D-83E6-2371CBAD1146Q36087118-6AC10C93-3F8D-4057-AA14-2DB3721D1F67Q36590359-FF1A844E-71F7-4CD7-BCB6-015FFCC879BEQ36619367-875EFE01-788A-4C4A-8EC6-A5CA822A6137Q36923241-64182D21-7BA5-4F73-9B34-898C3BC81D2DQ37285373-FDADA492-EAE9-4C72-8546-439502B8BDA4Q37640945-E88AD5DD-65BC-4840-9DF6-0091CA85B22CQ38013583-5B45E718-5901-4819-AF07-9CE116C9B937Q38109906-AAD11986-2B31-422A-96AD-2A18FA0AC1CEQ38135335-8D4492D2-50B3-46FD-922C-22ED636AE39BQ38553346-4143E38C-91DA-4D18-8E9A-0E2AC86E7FD6Q38986713-70AEC55D-119C-4965-931E-8FD12EDBE2A2Q40092025-E177DE6E-7E73-410E-B9A9-2BDAE3FE943DQ40649226-8DE0C1AD-B290-4D02-AFD7-BC9BD2E130F2Q41645294-030B15E4-E690-4839-BD35-912D93789BB8Q47176561-552F0F35-3785-4EE8-8450-1042DACAA7D8Q47998109-E6785C2F-023D-4FC0-BAB6-96AD5D5A14E0Q55407136-05385590-6249-439A-955E-B8447C3AF591Q59224446-BC7C0572-FC27-4107-ABE7-33E0D01FE58C
P2860
In vivo distribution of β2 glycoprotein I under various pathophysiologic conditions.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年学术文章
@wuu
2011年学术文章
@zh
2011年学术文章
@zh-cn
2011年学术文章
@zh-hans
2011年学术文章
@zh-my
2011年学术文章
@zh-sg
2011年學術文章
@yue
2011年學術文章
@zh-hant
name
In vivo distribution of β2 glycoprotein I under various pathophysiologic conditions.
@en
In vivo distribution of β2 glycoprotein I under various pathophysiologic conditions.
@nl
type
label
In vivo distribution of β2 glycoprotein I under various pathophysiologic conditions.
@en
In vivo distribution of β2 glycoprotein I under various pathophysiologic conditions.
@nl
prefLabel
In vivo distribution of β2 glycoprotein I under various pathophysiologic conditions.
@en
In vivo distribution of β2 glycoprotein I under various pathophysiologic conditions.
@nl
P2093
P50
P1433
P1476
In vivo distribution of β2 glycoprotein I under various pathophysiologic conditions
@en
P2093
Andrea Lorenzon
Claudia Grossi
Francesco Tedesco
Stefania Biffi
P304
P356
10.1182/BLOOD-2011-01-333617
P407
P50
P577
2011-07-26T00:00:00Z